

# PATENT COOPERATION TREATY

PLM  
DMC  
LIT

From the INTERNATIONAL SEARCHING AUTHORITY

To:  
**FISH & RICHARDSON P.C.**  
 Attn. Myers, Louis  
 225 Franklin Street  
 Boston, Mass. 02110-2804  
 UNITED STATES OF AMERICA

FISH &  
RICHARDSON P.C.  
1002 6 DT  
RECEIVED

**PCT**

NOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL SEARCH REPORT  
OR THE DECLARATION

(PCT Rule 44.1)

Date of mailing (day/month/year)		15/10/2001
Applicant's or agent's file reference <b>10448-025W01</b>	FOR FURTHER ACTION      See paragraphs 1 and 4 below	
International application No. <b>PCT/US 01/ 07138</b>	International filing date (day/month/year) <b>05/03/2001</b>	
Applicant <b>MILLENNIUM PHARMACEUTICALS, INC.</b>		

1.  The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.

**Filing of amendments and statement under Article 19:**

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

**When?** The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

**Where?** Directly to the International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland  
Fascimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

Rec'd no Report 12/15/01  
Abstract 11/15/01  
AT (00) 11/15/02  
CPB

2.  The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3.  With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

Docketed By Billing Secretary	
Due Date: <b>12/15/01; 11/15/01; 11/15/02</b>	
Deadline: _____	
Initials: <b>CL</b>	

4. Further action(s): The applicant is reminded of the following:

Shortly after **18 months** from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

Within **19 months** from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within **20 months** from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority   European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer  Sandra De Jong-van Dam
---	--

## NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

### INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

#### What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

**When?** Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

#### Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been filed, see below.

**How?** Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

#### What documents must/may accompany the amendments?

##### Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

## NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

**The following examples illustrate the manner in which amendments must be explained in the accompanying letter:**

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:  
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]:  
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:  
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or  
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:  
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

### **"Statement under article 19(1)" (Rule 46.4)**

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

**It must be in the language in which the international application is to be published.**

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

### **Consequence if a demand for international preliminary examination has already been filed**

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

### **Consequence with regard to translation of the international application for entry into the national phase**

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

## PATENT COOPERATION TREATY

## PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>10448-025W01</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/US 01/ 07138</b>	International filing date ( <i>day/month/year</i> ) <b>05/03/2001</b>	(Earliest) Priority Date ( <i>day/month/year</i> ) <b>07/03/2000</b>
Applicant <b>MILLENNIUM PHARMACEUTICALS, INC.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 9 sheets.

It is also accompanied by a copy of each prior art document cited in this report.

**1. Basis of the report**

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
  - the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).
- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :
  - contained in the international application in written form.
  - filed together with the international application in computer readable form.
  - furnished subsequently to this Authority in written form.
  - furnished subsequently to this Authority in computer readable form.
  - the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
  - the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2.  **Certain claims were found unsearchable** (See Box I).

3.  **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

- the text is approved as submitted by the applicant.
- the text has been established by this Authority to read as follows:

26583, A SERINE/THREONINE PHOSPHATASE AND USES THEREOF

5. With regard to the **abstract**,

- the text is approved as submitted by the applicant.
- the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No. —

- as suggested by the applicant.
- because the applicant failed to suggest a figure.
- because this figure better characterizes the invention.

None of the figures.

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US 01/07138

**Box III TEXT OF THE ABSTRACT (Continuation of item 5 of the first sheet)**

The invention provides isolated nucleic acids molecules, designated 26583 nucleic acid molecules, which encode serine/threonine phosphatase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 26583 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 26583 gene has been introduced or disrupted. The invention still further provides isolated 26583 proteins, fusion proteins, antigenic peptides and anti-26583 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 01/07138

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 7 C12N15/55 C12N15/11 C12N15/68 C12N9/16 C12Q1/68  
 A61K38/46 G01N33/53 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
 IPC 7 C12N C12Q A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EMBL, EPO-Internal, WPI Data, PAJ, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HUANG B ET AL.: "Isoenzymes of pyruvate dehydrogenase phosphatase: DNA-derived amino acid sequences, expression, and regulation." <i>JOURNAL OF BIOLOGICAL CHEMISTRY</i> , vol. 273, no. 28, 10 July 1998 (1998-07-10), pages 17680-17688, XP002178212 ISSN: 0021-9258 Note: 89.1% nt seq identity of rat PDP1 cDNA with SEQ ID NO:1 in 1817 nt overlap (11-1815:342-2158), 98.02% aa seq identity of rat PDP1 with SEQ ID NO:2 in 537 aa overlap (1-537:1-537) the whole document figure 1A page 17684, left-hand column, line 28-30	1, 3-8, 10-19, 21, 22
Y	-----	2, 9, 20, 23-36
	-/-	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

26 September 2001

Date of mailing of the international search report

15/10/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

van de Kamp, M

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/07138

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EM_EST 'Online! EMBL; ID AI024308, AC AI024308, 19 June 1998 (1998-06-19) NATIONAL CANCER INSTITUTE, CANCER GENOME ANATOMY PROJECT (CGAP): "ov67f02.x1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:1642395 3' similar to SW:PDP_BOVIN P35816 'PYRUVATE DEHYDROGENASE ;, mRNA sequence" XP002178218	1,8
Y	Note: 100.0% nt seq identity with SEQ ID NO:1 in 373 nt overlap (1-373:761-389), 100.0% aa seq identity of translated sequence with aa 1-100 of SEQ ID NO:2 the whole document ---	2,9,20, 23-36
X	DATABASE EM_EST 'Online! EMBL; ID HS695159, AC H10695, 2 July 1995 (1995-07-02) HILLIER L ET AL.: "ym07h07.r1 Soares infant brain 1NIB Homo sapiens cDNA clone IMAGE:47378 5' similar to SP:PDP_BOVIN P35816 'PYRUVATE DEHYDROGENASE ;, mRNA sequence" XP002178219	1,8
Y	Note: 96.8% nt seq identity with SEQ ID NO:1 in 443 nt overlap (1-443:985-1420), 89.0% aa seq identity of translated sequence with aa 176-320 of SEQ ID NO:2 the whole document ---	2,9,20, 23-36
		-/-

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/07138

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EM_OM 'Online! EMBL; ID BTPHOS, AC L18966, 10 November 1993 (1993-11-10) LAWSON J E ET AL.: "Bos taurus pyruvate dehydrogenase phosphatase mRNA, complete cds" XP002175558 Note: 91.1% nt seq identity with SEQ ID NO:1 in 1752 nt overlap (114-1861:411-2157), 98.0% aa seq identity with SEQ ID NO:2 in 537 aa overlap (1-537:1-537) the whole document	1,8
X	-& LAWSON J E ET AL.: "Molecular cloning and expression of the catalytic subunit of bovine pyruvate dehydrogenase phosphatase and sequence similarity with protein phosphatase 2C" BIOCHEMISTRY, vol. 32, no. 35, 7 September 1993 (1993-09-07), pages 8987-8993, XP002178213 the whole document ---	1,3,5,7, 8,11-19, 21,22
A	WO 97 35018 A (UNIV NEW YORK) 25 September 1997 (1997-09-25) the whole document page 6, line 6 -page 10, line 26 ---	13-36
A X	EP 0 874 052 A (BIOPH BIOTECH ENTW PHARM GMBH) 28 October 1998 (1998-10-28) the whole document ---	13-36
A X	WO 00 00205 A (RADEMACHER THOMAS WILLIAM ;UNIV LONDON (GB); MCLEAN PATRICIA (GB);) 6 January 2000 (2000-01-06) page 4, line 26 -page 5, line 6 page 19, line 8-17 figure 4C ---	
A	STANSBIE D: "REGULATION OF THE HUMAN PYRUVATE DEHYDROGENASE EC-1.2.4.1 COMPLEX" CLINICAL SCIENCE AND MOLECULAR MEDICINE, vol. 51, no. 5, 1976, pages 445-452, XP001024579 ISSN: 0301-0538 abstract page 446, right-hand column, line 30 -page 447, left-hand column, line 17 page 447, right-hand column, line 15 -page 448, left-hand column, line 13 page 448, right-hand column, line 38 -page 449, right-hand column, line 17; figure 2 ---	
	-/--	

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/07138

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SHEU K-F R ET AL: "PYRUVATE DEHYDROGENASE COMPLEX ACTIVITY IN NORMAL AND DEFICIENT FIBROBLASTS" JOURNAL OF CLINICAL INVESTIGATION, vol. 67, no. 5, 1981, pages 1463-1471, XP001024581 ISSN: 0021-9738 abstract figure 4 ---	
A	ITO M ET AL: "DECREASE OF PYRUVATE DEHYDROGENASE PHOSPHATASE ACTIVITY IN PATIENTS WITH CONGENITAL LACTIC ACIDEMIA" CLINICA CHIMICA ACTA, vol. 209, no. 1-2, 1992, pages 1-7, XP001024582 ISSN: 0009-8981 abstract ---	
A	BARFORD D: "Molecular mechanisms of the protein serine/threonine phosphatases" TIBS TRENDS IN BIOCHEMICAL SCIENCES, vol. 21, no. 11, 1 November 1996 (1996-11-01), pages 407-412, XP004071015 ISSN: 0968-0004 abstract page 410, right-hand column, line 49 -page 411, right-hand column, line 31 ---	
P,X	WO 00 73509 A (BANVILLE STEVEN C ;GREENAWALT LILA B (US); INCYTE GENOMICS INC (US) 7 December 2000 (2000-12-07) Note: 99.0% nt seq identity of SEQ ID NO:46 with SEQ ID NO:1 in 1634 nt overlap (302-1935:418-2048), 98.5% aa seq identity of translated sequence with SEQ ID NO:2 in 529 aa overlap page 10, line 5-7 page 19, line 22 page 26, line 22 page 58, line 27 -page 60, line 19 page 123-170 tables 2 and 3: SEQ ID NO:25 claims 1-19 ---	1-36
P,X	DATABASE WPI Section Ch, Week 200107 Derwent Publications Ltd., London, GB; Class B04, AN 2001-050441 XP002178221 & CN 1 267 727 A (SOUTHERN RES CENT NAT HUMAN GENE GROUP), 27 September 2000 (2000-09-27) abstract ---	1-18

## INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/07138

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>DATABASE EM_HUM 'Online! EMBL; ID AF155661, AC AF155661, 4 May 2000 (2000-05-04)</p> <p>PENG Y ET AL.: "Homo sapiens pyruvate dehydrogenase (PDH) mRNA, complete cds" XP002178220</p> <p>Note: 99.3% nt seq identity with SEQ ID NO:1 in 1786 nt overlap (195-1974:417-2201), 99.4% aa seq ident of translated sequence with SEQ ID NO:2 in 537 aa overlap the whole document</p> <p>-&amp; HU R-M ET AL.: "Gene expression profiling in the human hypothalamus-pituitary-adrenal axis and full-length cDNA cloning." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 17, 15 August 2000 (2000-08-15), pages 9543-9548, XP002178217 abstract page 9546, right-hand column, line 68</p> <p>---</p>	1,2,8,9
P,X	<p>-&amp; HU R-M ET AL.: "Gene expression profiling in the human hypothalamus-pituitary-adrenal axis and full-length cDNA cloning." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 17, 15 August 2000 (2000-08-15), pages 9543-9548, XP002178217 abstract page 9546, right-hand column, line 68</p> <p>---</p>	1,2,8,9
E	<p>X</p> <p>WO 01 46394 A (PLOWMAN GREGORY D ;HILL RONALD J (US); SUGEN INC (US); WHYTE DAVID) 28 June 2001 (2001-06-28)</p> <p>Note: 99.6% nt seq identity of SEQ ID NO:10 with SEQ ID NO:1 in 1663 nt overlap (64-1725:417-2078), 99.4% aa seq ident of translated sequence with SEQ ID NO:2 in 537 aa overlap (109-1719:1-537) page 3, line 5 -page 43, line 8 tables 1-4 page 130, line 5-17 page 136, line 7-16 claims 1-29</p> <p>-----</p>	1-36

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

Continuation of Box I.2

Remark (2): Present claims 21 and 23-30 relate to an agent/compound defined by reference to a desirable characteristic or property, namely binding to a polypeptide of the invention or modulating the activity or the expression of a polypeptide or a nucleic acid of the invention. The claims cover all agents/compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such agents/compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the agents/compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to antibody and antisense molecules.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 01/07138

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  

Remark (1): Although claims 21 and 23–30, insofar as in vivo methods are concerned, are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  

see FURTHER INFORMATION sheet PCT/ISA/210
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/US 01/07138

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 9735018	A	25-09-1997	AU WO US US	2553097 A 9735018 A1 5976853 A 6066485 A		10-10-1997 25-09-1997 02-11-1999 23-05-2000
EP 0874052	A	28-10-1998	EP	0874052 A2		28-10-1998
WO 0000205	A	06-01-2000	AU EP WO	3940299 A 1091743 A1 0000205 A1		17-01-2000 18-04-2001 06-01-2000
WO 0073509	A	07-12-2000	AU WO AU WO AU WO	5320900 A 0073509 A2 5319400 A 0075298 A2 5316800 A 0111032 A1		18-12-2000 07-12-2000 28-12-2000 14-12-2000 05-03-2001 15-02-2001
CN 1267727	A	27-09-2000		NONE		
WO 0146394	A	28-06-2001	WO WO	0146394 A2 0155356 A2		28-06-2001 02-08-2001